Renal Damage. Captopri 1 Ena 1 apr i 1 Kinins

Similar documents
Takushi X. WATANABE, Koichiro KAWASHIMA* and Hirofumi SOKABE

Reducing proteinuria

Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009

Proceeding of the LAVC Latin American Veterinary Conference Oct , 2009 Lima, Peru

Blood Pressure. a change in any of these could cause a corresponding change in blood pressure

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives

The Antihypertensive Effect of Sesame Seed-derived Products

Responsiveness vs. basal activity of plasma ANG II as a determinant of arterial pressure salt sensitivity

ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.

Data Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR VETERINARY MEDICINE

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES

Effects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide

Urinary Kallikrein Excretion in Hypertensive Man

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure

ARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists

ACE. Inhibitors. Quiz feedback

Oral Calcium Treatment Lowers Blood Pressure in Renovascular Hypertensive Rats by Suppressing the Renin-Angiotensin System

Patterns of Sodium Excretion During Sympathetic Nervous System Arousal. Gregory A. Harshfield, Derrick A. Pulliam, and Bruce S.

Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories

First line treatment of primary hypertension

SPECIAL PATHOPHYSIOLOGY HYPERTENSION

Summary 255 Research Summary

LXIV: DRUGS: 4. RAS BLOCKADE

Tread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease

SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection

Dr Doris M. W Kinuthia

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Hypertensive Urgencies And Emergencies

Amlodipine plus Lisinopril Tablets AMLOPRES-L

Analysis of AVP functions via V1a and V1b receptors with knockout mice. Akito Tanoue

Chapter 10 Worksheet Blood Pressure and Antithrombotic Agents

Salt Sensitivity: Mechanisms, Diagnosis, and Clinical Relevance

Standardization of a fluorimetric assay for the determination of tissue angiotensin-converting enzyme activity in rats

Haemodynamic and humoral effects of oral perindopril, an

Renal Blood flow; Renal Clearance. Dr Sitelbanat

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

Pressure Diuresis 9 Sample Student Essays

Diabetic Nephropathy in Spontaneously Diabetic Torii (SDT) Rats

Section 3, Lecture 2

Year 2004 Paper two: Questions supplied by Megan 1

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

The role of angiotensin II (AngII) in maintaining

Olmesartan is used for treating high blood pressure (hypertension) in adult patients.

Perioperative use of angiotensin blockade

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Relation Between Sodium Intake, Renal Function, and the Regulation of Arterial Pressure. Jeffrey L. Osborn

Potassium, Aldosterone, and Hypertension: How Physiology Determines Treatment. Jamie Johnston, MD University of Pittsburgh School of Medicine

HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP

Risk Management Plan

Special Lecture 11/08/2013. Hypertension Dr. HN Mayrovitz

Systolic Blood Pressure Intervention Trial (SPRINT)

IN this issue of Hypertension is an article by Kimura and his colleagues

The Relationship between the Intrarenal Dopamine System and Intrarenal Renin-angiotensin System Depending on the Renal Function

HEART FAILURE SUMMARY. and is associated with significant morbidity and mortality. the cornerstone of heart failure treatment.

A guideline on Neonatal Hypertension

Disclosure of Relationships

Aspirin has perhaps the broadest spectrum

Case Study in Chronic Renal Failure

Conversion of losartan to lisinopril

CRAIOVA UNIVERSITY OF MEDICINE AND PHARMACY FACULTY OF MEDICINE ABSTRACT DOCTORAL THESIS

Mechanisms responsible for postmenopausal hypertension in a rat model: Roles of the renal sympathetic nervous system and the renin angiotensin system

In nocturnal enuresis

Relaxation responses of aortic rings from salt-loaded high calcium fed rats to potassium chloride, calcium chloride and magnesium sulphate

Preventing the cardiovascular complications of hypertension

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

Renal Physiology Part II. Bio 219 Napa Valley College Dr. Adam Ross

Oxidative Stress Unify the Pathophysiological Mechanism of Experimental Hypertension and Diabetes of Spontaneously Hypertensive Stroke-Prone Rats

THE IMPACT OF CCB AND RAS INHIBITOR COMBINATION THERAPY TO PREVENT CKD INCIDENCE IN HYPERTENSION AND ADVANCED ATHEROSCLEROSIS

Effect of multiple doses of losartan on the pharmacokinetics

Dr.Nahid Osman Ahmed 1

Comparison of a New Renin Inhibitor and Enalaprilat in Renal Hypertensive Dogs

Introduction. Factors affecting blood pressure: 1-COP = HR X SV mainly affect SBP. 2-TPR = diameter of arterioles X viscosity of blood affect DBP

ACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )

The antihypertensive and diuretic effects of amiloride and. of its combination with hydrochlorothiazide

The pharmacokinetics and dose proportionality of cilazapril

Inflammation in Renal Disease

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Acute Kidney Injury. APSN JSN CME for Nephrology Trainees May Professor Robert Walker

Tiny Jaarsma Linköping University No conflict of interest

COMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan

Since 1898, when renin was isolated from

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Three types of diets (casein-rich, whey protein-rich and milk fat-rich) were

COMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC

Cardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention

by Converting Enzyme Inhibition in Essential Hypertensives

Agenda. Management of Accelerated Hypertension (Updated in 2017) Salwa Roshdy Prof. of Cardiology Assiut University CardioEgypt 23/2/2017 2/27/2017

Antihypertensives. Diagnostic category

International Journal of Pharma and Bio Sciences

Mechanism: 1- waterretention from the last part of the nephron which increases blood volume, venous return EDV, stroke volume and cardiac output.

THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

Enalapril in heart failure

Renal Reabsorption & Secretion

Physiology (4) 2/4/2018. Wael abu-anzeh

Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:

TUBULOPATHY Intensive Care Unit Sina Hospital

Transcription:

CLIN. AND EXPER.THEORY AND PRACTICE, A9(2&3), 409413 (1987) PREVENTION OF RENAL DAMAGE AND DECREASE OF URINARY KININS EXCRETION BY CHRONIC TREA"TS WITH ENALAPRIL AND CAPTOPRIL IN STROKEPRONE SPONTANEOUSLY HYPERTENSIVE RATS Koichiro Kawashima, Takushi X. Watanabe*, Hirofumi Sokabe* and Ken Saito** Department of Pharmacology, Kyoritsu College of Pharmacy, Tokyo, Departments of *Pharmacology and **Pathology, Jichi Medical School, Tochigiken, Japan. Key words: Renal Damage SH3SP Captopri 1 Ena 1 apr i 1 Kinins INTRODUCTION: The antihypertensive mechanism of converting enzyme inhibitors (CEI) has not been completely established yet (1). It has been suggested that accumulation of hypotensive vasodilator kinins in the kidney in addition to the reduced formation of angiotensin (ANG) I1 could also contribute to the antihypertensive effect of CEI (2). The strokeprone spontaneously hypertensive (SHRSP) rat is an excellent model for the study on antihypertensive effect of CEI because its extremely high blood pressure depends partly on the activated reninangiotensin (RA) system (3) and its responsiveness to CEI has been well confirmed in our previous studies (46). We have observed that enalapril tends to decrease urinary kinins excretion (UKINV) in SHRSP rats in the shortterm study (6). To investigate further the possible involvement of renal kinins in the antihypertensive effect of CEI, we studied effects of chronic treatments with enalapril and captopril on blood pressure, UKINV and renal damage in SHRSP rats. MATERIALS AND METHODS: Urine and the kidney samples sere obtained from 14 to 15weekold male SHRSP rats used in the previous study 40 9 Copyright 0 1987 by Marcel Dekker, Inc.

W K 3 v) W 41 0 mmhg 300 250 K n n 0 4 m 200 4 a I SHRSP KAWASHIMA ET AL. p (5) 7 l 0 H20 L L m 5ml/kg. PO (10) **! (10) 5 0 enalapril 10mg/kg, PO (10) A captopril 30mg/kg, PO (10) E I I 1 I I I I I 1 t 1 I I 0 1 2 3 4 5 6 7 8 9 1 0 1 1 w k FIG. 1. Effects of enalapril and captopril on blood pressure in SHRSP rats. Treatments were started at 14 to 15 weeks of age. Values are mean 5 S.E.M. *P < 0.05, **P < 0.01, compared to the control. (5). Rats were treated with orally administered either water as control, enalapril (10 mg/kg), or captopril (30 mg/kg) once daily for 11 weeks. Food and water were offered ad libitum. Blood pressure was determined indirectly by tailcuff method (5). At the end of the treatment, direct mean blood pressure (MBP) was monitored through the indwelling aortic catheter (3). On the 3rd day, and during the 5th and 10th week of the treatment, rats were placed in individual metabolism cages with water and powdered rat food offered ad libitum. Twentyfourhr urine sample was collected into a graduated cylinder containing 100 p1 of 6 N HC1. UKINV was determined by a radioimmunoassay (7) * Histological study on the kidney was performed on the 4 vm sections stained with hematoxylineosin or Elasticavan Giesen. The severity of renal damage was graded from 0 to 3 according to the following criteria: grade 0, no discernible vascular lesion; grade 1, a few vascular lesions without remarkable parenchymal

PREVENTION OF RENAL DAMAGE 41 1 1 1 Hz0 5ml/kg, PO enalaprii captopril lomg/kg, PO 30mg/kg, PO ** ** 1 wk 5wk lowk FIG. 2. Effects of enalapril and captopril on urinary kinins excretion. Values are mean 2 S.E.M. Data of the 1st week were obtained on the 3rd day of the treatment. **P < 0.01, compared to the control. destruction; grade 2, scattered vascular lesions with focal parenchymal destruction; grade 3, disseminated vascular lesions with remarkable parenchymal destruction. RESULTS: In enalapril and captopril treated groups, a rapid and significant decrease of blood pressure from about 250 to around 200 mmhg was observed soon after the beginning of the treatment (FIG. 1) (5). Although blood pressure in the drug treated groups tended to return gradually towards the pretreatment level during the treatment, it was significantly lower than that in the control group at almost all the points of the determination.

41 2 KAWASHIMA ET AL. TABLE 1 Effects of chronic treatments with enalapril and captopril on the severity of renal damage in adult SHRSP rats Severity of renal damage Treat men t mean 2 S.E.M. of Grade: 0 1 2 3 severity grade Enalapril 4 4 2 0 0.8 2 0.3** (10 mgkg per day) Captopril 1 4 4 1 1.5 2 0.3** (30 mg/kg per day) Figures indicate number of rats.?data of rats died before completion of the experiments were included. **P < 0.01, compared to the control. Criteria for severity grade of the renal damage are shown in the section of MATERIALS AND METHODS. Urine volume (W) in the control group increased significantly during the 5th and 10th week of the treatment ( 5). A positive correlation was observed between W and MBP (r = 0.724). As early as on the 3rd day of the treatment, U K ~ ~ in V drug treated groups tended to decrease. Marked decreases in UKINV in the drug treated groups were observed during the 5th and 10th week of the treatment (P < 0.01) (FIG. 2). A positive correlation was found between ~ I N V and W during the 10th week of the treatment (r = 0.812). Severe vascular lesions and remarkable parenchymal destruction were observed in the control group. The value for renal damage in the control group was significantly higher than those in groups treated with CEI (P < 0.01) (TABLE 1). The severity of renal damage positively well correlated with the MBP (r = 0.896), and with W (r = 0.746). DISCUSSION: Chronic treatments with enalapril and captopril produced significant reductions of blood pressure and UK~NV, and prevented renal damage in adult SHRSP rats. UKINV tended to decrease soon after the beginning of the treatment and was significantly decreased during the chronic treatment with CEI. These results are consistent with the previous study (6). Thus, these data do not support the hypothesis of possible additional involvement of renal kinins in the antihypertensive effect of CEI. In the SHRSP with activated RA system (3), enalapril and captopril appear to

PREVENTION OF RENAL DAMAGE 41 3 produce antihypertensive effect through reduction of ANG I1 formation. A good positive correlation between W and UKINV suggest that renal kinins are washed out from the tubules by urine flow. A good positive correlation between hbp and renal damage indicates that CEI prevented renal damage through the reduction of blood pressure and ANG I1 formation. Furthermore, a positive correlation between W and MBP suggests that pressure diuresis may be involved in the increased W found in the control group. REFERENCES 1. Sweet CS, Blaine EH: Angiotensinconverting enzyme inhibitors. In: Pharmacology of Antihypertensive Drugs (Ed. van Zwieten PA), Elsevier, Amsterdam, 1984, p. 343363. 2. Johnston CI, Clappison BH, Anderson, WP, Yasujima M: Effect of angiotensinconverting enzyme inhibition on circulating and local kinin levels. Am J Cardiol 1982; 49: 14011404. 3. Kawashima K, Shiono K, Sokabe H: Variation of plasma and kidney renin activities among substrains of spontaneously hypertensive rats. Clin Exp Hyper 1980; 2: 229245. 4. Watanabe TX, Kawashima K, Saito K, Sokabe H: Effects of longterm treatments with captopril on blood pressure and renin activity in the strokeprone spontaneously hypertensive rats. Japan J Pharmacol 1980; 30: 819827. 5. Watanabe TX, Kawashima K, Sokabe H: Chronic effects of enalapril on blood pressure, stroke, plasma renin, urinary electrolytes and PGE2 excretion in the strokeprone spontaneously hypertensive rats. Japan J Pharmacol 1985; 38: 419427. 6. Kawashima K, Kimura M, Watanabe TX, Sokabe H, Kobayasi Y: Effects of enalapril and captopril on urinary excretion of kinins and electrolytes in strokeprone spontaneously hypertensive rats. Japan J Pharmacol 1985; 39:415417. 7. Shimamoto K, Ando T, Nakao T, Tanaka S, Sakuma M, Miyahara M: A sensitive radioimmunoassay method for urinary kinins in man. J Lab Clin Med 1978; 91: 721728.